Zicam and Vicks Win Over Cold Medicine Shoppers, But Loyalty Lies With Price and Symptom Relief: Report
Leaning Into Targeted Products
The Extra Strength segment is one area, in particular, where consumer goods companies can elevate promotional efforts to differentiate themselves from competitors. It claimed the highest category share at 37.3% between September 29 and December 28.
New product types, like Gluten-Free Lozenges, are also gaining traction, providing brands with an opportunity to capitalize on consumer preferences for specialized offerings.
Leading the Pack
Vicks leads in the Sinus Pressure category with 96.7% share, while Bayer leads in Congestion Relief (37.2% market share). Additionally, Vicks grew by 2.1% in the Spray segment.
Zicam is a dominant brand in the $6-10 price band, which contributes 40% of units and 25.5% of revenue. It also had the highest organic growth in the Drops category, growing to 14.27% market share.